Celebrity Chef Carla Hall and The Fresh Market Team Up to Support Alzheimer's Association During Month of June
GREENSBORO, N.C.--(BUSINESS WIRE)--The Fresh Market is proud to partner with Alzheimer's Association and celebrity chef, author and TV personality Carla Hall to raise funds and awareness for Alzheimer's disease during Alzheimer's and Brain Awareness Month this June. From June 1-30, The Fresh Market will donate 10% of the purchase price of Hall's Sweet Heritage Butter Tart to the Alzheimer's Association.
Carla Hall, beloved for her appearance on Bravo's Top Chef is now using her voice – and her passion for food – to make a meaningful impact in the fight against Alzheimer's disease.
Share
Carla Hall, beloved for her appearance on Bravo's Top Chef and Top Chef: All Stars, is known for her philosophy of cooking with love. She is now using her voice – and her passion for food – to make a meaningful impact in the fight against Alzheimer's disease in honor of her beloved grandmother, Freddie Mai Price Glover.
'My Granny had a larger-than-life personality, but what I remember most is her food — it was always made with love,' said Hall. 'Ironically, it was changes in her cooking that first signaled something was wrong. That's when we learned she had Alzheimer's.'
Inspired by her grandmother's legacy, Hall is an outspoken Celebrity Champion for the Alzheimer's Association. She speaks out by sharing her story to raise Alzheimer's awareness, break down the stigma surrounding the disease and generate greater public support for the cause.
"The Alzheimer's Association is thrilled to collaborate with The Fresh Market and Carla Hall during Alzheimer's and Brain Awareness Month this June,' said Sarah Fried, Alzheimer's Association vice president of Corporate Initiatives. 'This partnership will help fund critical support services and research, while encouraging others to join us in the fight to end this disease.'
Alzheimer's impacts millions of families. The numbers are startling. For the first-time ever, there are now over 7 million Americans living with Alzheimer's disease and almost 12 million family members and friends serving as their unpaid caregivers, according to the Alzheimer's Association Alzheimer's Disease Facts and Figures report.
'It's not often we have the opportunity to collaborate with two incredible partners through a single initiative,' said Emily Turner, Chief Marketing Officer at The Fresh Market. 'We're honored to join forces with Carla Hall and channel our shared passion for food into raising awareness of Alzheimer's disease and supporting the vital work of the Alzheimer's Association in our communities.'
Carla Hall's Sweet Heritage Butter Tarts are available in Apple, Cherry, Peach, Strawberry Rhubarb, and Fruits of the Orchard and feature a buttery oat crust with a hint of almond, a nod to the flavoring Carla's grandmother loved.
The partnership will be active in all The Fresh Market locations throughout the month of June.
About The Fresh Market
Rated by USA Today as one of America's Best Customer Service Companies in 2025, voted #1 in three categories by USA Today's 10Best Readers' Choice Awards for 2024—"Best Grocery Store Bakery," "Best Grocery Store Deli," and "Best Grocery Store Prepared Foods"—and recognized for three consecutive years as the 'Best Grocery Store in America.' The Fresh Market currently operates more than 170 grocery stores in 22 states across the U.S. and one Spirits & Wine store, inspiring guests to discover new flavors and cook with confidence. For more information, please visit www.thefreshmarket.com or follow the company on Facebook, Instagram, TikTok, X and Pinterest.
About the Alzheimer's Association
The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
IVF parents are spending thousands to predict their babies' chances of having Alzheimer's, cancer and heart disease
Maybe she's born with it, maybe it's … genetic optimization? Prospective parents using in vitro fertilization (IVF) will soon be able to select embryos based on their potential risk for diseases — including illnesses that develop later in life — thanks to a groundbreaking $5,999 service announced this week by a US biotech company. 'Before there's a heartbeat, there's DNA,' Kian Sadeghi, founder and chief executive of Nucleus Genomics, said in a statement. 'One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage.' The popular fertility treatment involves removing eggs from a woman's ovaries and fertilizing them with sperm in a lab. The resulting embryo — which could be frozen or fresh — is placed into the uterus, where it hopefully implants in the uterine wall and sparks a pregnancy. Before implantation, many IVF clinics already screen embryos for genetic abnormalities — such as extra chromosomes or gene mutations — that can lead to failed implantations, miscarriages, birth defects or inherited disorders. But the first-of-its-kind service from Nucleus Genomics takes things a step further. The company just launched Nucleus Embryo, a new software platform that lets potential parents dig deep into the full genetic blueprint of their embryos before choosing which one to implant. The tool lets IVF patients compare the DNA of up to 20 embryos, screening them for more than 900 conditions — including Alzheimer's, Type 2 diabetes, heart disease and several forms of cancer. It doesn't stop there. The program also flags potential mental health conditions like depression and schizophrenia and even ranks cognitive traits like IQ. Parents can also get a look at cosmetic and physical features, from height, baldness and BMI to eye and hair color. The company isn't promising perfection. Instead, the software generates a so-called polygenic risk score that will give parents the probability of how likely it is an embryo might develop certain traits or diseases. Ultimately, it's up to the parents to decide which qualities matter most to them. For those looking to decode the results, genetic counseling sessions are available. 'Lifespan has dramatically increased in the last 150 years,' Sadeghi told the Wall Street Journal. 'DNA testing to predict and reduce chronic disease can make it happen again.' The practice, known as polygenic embryo screening, is already highly controversial in the medical world, according to a report published by Harvard Law School's Petrie-Flom Center. Critics warn that allowing parents to screen embryos for risks like depression or diabetes could deepen stigma and discrimination against people living with those conditions. Meanwhile, disability advocates argue it promotes the harmful idea that disability is something to be fixed, not a natural part of human diversity. And when it comes to choosing embryos for traits like intelligence or athleticism, critics say we're sliding into designer baby territory — a modern form of eugenics that favors the rich, reinforcing social and healthcare inequalities. Still, the public appears open to some aspects of the tech. A 2023 survey found that 77% of Americans support using it to screen embryos for the likelihood of developing certain physical conditions, while 72% back screening for mental health risks. Proponents argue it's no different from vaccination — a preventive tool, not a judgment on those with the condition. But when it comes to non-medical traits, support drops fast: only 36% back screening embryos for behavioral traits and just 30% for physical features like height or eye color.
Yahoo
8 hours ago
- Yahoo
Tips to take care of your brain for Alzheimer's and Brain Health Awareness Month
June is Alzheimer's and Brain Health Awareness Month and people hoping to spread that awareness said there are things you can do to take charge of your brain health. Brain changes that cause Alzheimer's can begin 20 years or more before symptoms appear. Work to start on Rockdale Road next week Doing things like exercising, eating right, getting good quality sleep, and controlling blood pressure can improve brain health and reduce the risk of cognitive decline. While age and family history are factors, these can naturally help you to reduce your risk. Millcreek man says over $1000 was stolen from EBT account 'It's not just the individual with the diagnosis, but it's the over 480 thousand caregivers here in the state of Pennsylvania that are providing that care. It's the family members that are in that circle of care who need that information and support. We want people to know they're not alone,' said Sara Murphy, vice president of programs and services for the Alzheimer's Association Greater PA Chapter. Early detection of cognitive diseases is crucial. The Alzheimer's Association also has a help line that anyone can call to get support at 1-800-272-3900. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
10 hours ago
- Yahoo
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) by anygal on r/investing on Reddit. In this article, we will summarize the bulls' thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)'s share was trading at $9.33 as of 30th May. ACOG's forward P/E was 26.88 according to Yahoo Finance. A chemist in a laboratory analyzing data from the various therapeutic tests conducted. Alpha Cognition Inc. (NASDAQ: ACOG) represents a potentially overlooked opportunity in the Alzheimer's treatment space, having recently launched its oral drug, Zunveyl, at the end of March. With a current market cap of $150 million and $45 million in cash, the company is targeting the underserved segment of the Alzheimer's population—specifically, the 50% of patients in long-term care (LTC) not taking any current medications due to severe side effects. Unlike other galantamine-based drugs, Zunveyl significantly slows disease progression and improves short-term memory with a markedly better safety profile—only one serious side-effect case was reported in its Phase 3 trials, versus a 50% rate seen in traditional options. The drug's Medicare coverage further eases affordability, lowering monthly out-of-pocket costs to $30–$190. Initial demand appears promising, with nearly 500 patients starting treatment in the first two weeks of launch. Even a modest 1% market penetration into the LTC segment could yield $135 million in annual revenue, with $67.5 million in net income assuming 50% margins. A 5% penetration would put net income at $675 million, dwarfing the current valuation. Alpha Cognition has also secured a distribution deal with a major Chinese pharmaceutical firm, creating a royalty-based revenue stream in Asia. While the upside is substantial, key risks remain—most notably, the emergence of unforeseen serious side effects post-launch, which could lead to FDA scrutiny or suspension of sales. Still, the market's underreaction and the company's positioning as a safer, effective alternative in a high-need space make ACOG a high-upside, high-conviction bet for risk-tolerant investors. Previously, we have covered ACOG in March 2025 wherein we summarized a by BullishDoctor on Twitter. The user highlighted that Alpha Cognition Inc.'s drug ZUNVEYL addressed the major side effects of existing Alzheimer's treatments, making it highly tolerable and poised for adoption in long-term care facilities, a $2 billion market. The company was pre-revenue but launched in March 2025 with strong physician support, a nearly complete sales force, and promising catalysts like a Phase 4 study and sublingual formulation, projecting breakeven within three years. Since our last coverage, the stock is up 61% as of 30th May. Alpha Cognition Inc. Common Stock (ACOG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held ACOG at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of ACOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
